Bristol-Myers Squibb Tops Q4 EPS by 9c
Bristol-Myers Squibb (BMY) reported Q4 EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.21...
Neutral
or
Bristol Myers Squibb Company BDR News & Analysis
-
-
Bristol-Myers Squibb earnings beat by $0.09, revenue topped estimates
Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported fourth quarter EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4B versus the...
-
Credit Suisse initiates coverage of large-cap pharma stocks - Merck started at outperform
By Sam Boughedda Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one...
-
Bristol-Myers Squibb Earnings, Revenue beat In Q3
Investing.com - Bristol-Myers Squibb (NYSE:BMY) reported on Wednesday third quarter {{erl-8142||earnings that beat analysts' forecasts and revenue that topped expectations. Bristol-Myers...
-
Bristol-Myers Squibb Tops Q3 EPS by 17c, Beats on Revenue, Offers FY22 Revenue Guidance
Bristol-Myers Squibb (BMY) reported Q3 EPS of $1.99, $0.17 better than the analyst estimate of $1.82. Revenue for the quarter came in at $11.22 billion versus the consensus estimate of...
-
Meta Platforms, Bristol-Myers Squibb, Boeing Earnings: 3 Things to Watch
By Liz Moyer Investing.com -- Stocks extended gains as investors absorbed a steady stream of earnings from big companies such as General Motors (NYSE:GM) and Coca-Cola Co (NYSE:KO). But...
-
Ventyx Biosciences Shares Surge, Key Overhang Removed Says Analyst
By Sam Boughedda Shares of Ventyx Biosciences Inc (NASDAQ:VTYX) are up significantly Monday (up 62.5% at the time of writing), with analysts pointing to the approval of Bristol Myers...
-
The Key for Amgen is the 'Lack of a Black Box' - Mizuho
By Sam Boughedda Amgen (NASDAQ:AMGN) was reiterated at Neutral with a $208 per share price target by a Mizuho analyst on Monday, despite the stock's decline during the session following the...
-
U.S. Stocks Rise as Investors Await August Inflation Reading
By Liz Moyer Investing.com -- U.S. stocks opened higher to start the week as investors awaited Tuesday’s report on inflation. At 10:00 ET (14:00 GMT) the Dow Jones Industrial Average rose...
-
Bristol-Myers Squibb Rallies as FDA's Approval of Sotyktu is a 'Best-case Scenario'
By Senad Karaahmetovic Shares of Bristol-Myers Squibb (NYSE:BMY) are up about 7% in premarket Monday after the U.S. FDA approved Deucravacitinib, now known as Sotyktu, for the treatment of...
-
Midday Movers: Pinduoduo, Bristol-Myers, Netflix and More
By Liz Moyer Investing.com -- U.S. stocks fell again after last week's remarks by Fed Chair Jerome Powell stoked rate fears. Here are the midday movers for Aug. 29: Pinduoduo...
-
Bristol Myers Squibb Sliding on Milvexian Readout, Analysts See Data as “Risky”
By Vlad Schepkov Shares of Bristol Myers Squibb (NYSE:BMY) are trading 6% lower on Monday on the news the company’s AXIOMATIC-SSP study of milvexian failed to achieve primary endpoint. Over...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
